on December 22, 2005
Published online before print December 22, 2005, doi: 10.1161/01.ATV.0000201289.83256.cf
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 3, 2005
Accepted on December 12, 2005
Lipoprotein-Associated Phospholipase A2 and Measures of Extracoronary Atherosclerosis. The Rotterdam Study
Isabella Kardys ;
From the Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, The Netherlands.
* To whom correspondence should be addressed. E-mail: j.witteman{at}erasmusmc.nl.
Objective--Lipoprotein-associated phospholipase A2 (Lp-PLA2) may be a new and independent predictor of cardiovascular events. The effect of Lp-PLA2 may be exerted through effects of the enzyme on the development of atherosclerosis. Therefore, we investigated the association between Lp-PLA2 activity and measures of extracoronary atherosclerosis.
Methods and Results--Lp-PLA2 activity was determined in a random sample of 1820 participants from the Rotterdam Study, a population-based cohort study in men and women 
55 years. Common carotid intima-media thickness, carotid plaques, ankle-arm index, and aortic calcification were examined. Atherosclerosis status could be assigned in 1609 participants. The age-adjusted odds ratio of having atherosclerosis at any site for the highest versus the lowest tertile of Lp-PLA2 activity was 1.86 (95% CI, 1.01 to 3.43) in men and 1.60 (95% CI, 1.08 to 2.37) in women. After additional adjustment for cholesterol, these associations attenuated or even disappeared. The odds ratios of having atherosclerosis at specific sites (carotid arteries and aortic-iliac-femoral tract) followed a similar pattern.
Conclusions--Although Lp-PLA2 has been found to be independently associated with cardiovascular events, the association with measures of subclinical extracoronary atherosclerosis found in this study strongly attenuated or even disappeared after adjustment for cholesterol.
Key words: atherosclerosis • inflammation • lipoprotein-associated phospholipase A2 • epidemiology
This article has been cited by other articles:
 |
|
 |
|
  F. J Khawaja and I. J Kullo Novel markers of peripheral arterial disease Vascular Medicine, November 1, 2009; 14(4): 381 - 392. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Suzuki, C. Solomon, N. S. Jenny, R. Tracy, J. J. Nelson, B. M. Psaty, C. Furberg, and M. Cushman Lipoprotein-Associated Phospholipase A2 and Risk of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study Circ Heart Fail, September 1, 2009; 2(5): 429 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Herrmann, D. Mannheim, C. Wohlert, D. Versari, F. B. Meyer, J. P. McConnell, M. Gossl, L. O. Lerman, and A. Lerman Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome Eur. Heart J., August 17, 2009; (2009) ehp309v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Hanusch-Enserer, G. Zorn, J. Wojta, C. W. Kopp, R. Prager, W. Koenig, M. Schillinger, M. Roden, and K. Huber Non-conventional markers of atherosclerosis before and after gastric banding surgery Eur. Heart J., June 2, 2009; 30(12): 1516 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Gardner, E. C. Reichert, M. K. Topham, and D. M. Stafforini Identification of a Domain That Mediates Association of Platelet-activating Factor Acetylhydrolase with High Density Lipoprotein J. Biol. Chem., June 20, 2008; 283(25): 17099 - 17106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mannheim, J. Herrmann, D. Versari, M. Gossl, F. B. Meyer, J. P. McConnell, L. O. Lerman, and A. Lerman Enhanced Expression of Lp-PLA2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques Stroke, May 1, 2008; 39(5): 1448 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Sabatine, D. A. Morrow, M. O'Donoghue, K. A. Jablonksi, M. M. Rice, S. Solomon, Y. Rosenberg, M. J. Domanski, J. Hsia, and for the PEACE Investigators Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2463 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lavi, J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans Circulation, May 29, 2007; 115(21): 2715 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zalewski, J. J. Nelson, L. Hegg, and C. Macphee Lp-PLA2: A New Kid on the Block Clin. Chem., September 1, 2006; 52(9): 1645 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher Lipoprotein-Associated Phospholipase A2 Predicts Future Cardiovascular Events in Patients With Coronary Heart Disease Independently of Traditional Risk Factors, Markers of Inflammation, Renal Function, and Hemodynamic Stress Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|